聚光科技（杭州）股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 聚光科技(杭州)股份有限公司(下称"公司") 监事会于2023年8月19日以电 子邮件、书面传真和专人送达等方式发出召开公司第四届监事会第七次会议通 知。本次会议于2023年8月25日以通讯表决的方式召开。本次会议应参加表决3 人，实际参加表决3人，本次会议的召集、召开符合《中华人民共和国公司法》 和公司章程的有关规定，会议决议合法、有效。监事会以通讯方式(传真)表决通 过了以下议案: 证券代码：300203 证券简称：聚光科技 公告编号：2023-038 监事赵玲、韦俊峥、程婷婷均是本员工持股计划的参与人，为关联监事，在 审议本议案时应回避表决。关联监事回避表决后，监事会对本议案无法形成有效 决议，本议案直接提交公司2023年第一次临时股东大会审议。 特此公告。 聚光科技（杭州）股份有限公司监事会 二〇二三年八月二十九日 一、审议通过了《关于 2023 年半年度报告及摘要的议案》 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告的程序符合 法 ...

1、股东大会届次：2023年第一次临时股东大会。 2、会议召集人：公司董事会 证券代码：300203 证券简称：聚光科技 公告编号：2023-042 聚光科技（杭州）股份有限公司 关于召开2023年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 经本公司第四届董事会第九次会议审议通过，聚光科技（杭州）股份有限公 司定于2023年9月13日14:30在杭州市滨江区滨安路760号聚光科技（杭州）股份 有限公司会议室召开公司2023年第一次临时股东大会。现将有关事项通知如下： 一、召开会议基本情况： 3、会议召开的合法、合规性：经公司第四届董事会第九次会议审议通过决 定召开2023年第一次临时股东大会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和公司《章程》的规定。 4、会议召开时间 现场会议时间：2023年9月13日14:30 网络投票时间：2023年9月13日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2023年9月13日 上午9:15-9:25，9：30-11：30，下午13：00-15：00；通过深圳证券交易所互联 ...

Financial Performance - The company's revenue for Q1 2023 was ¥519,460,164.32, representing a 3.40% increase compared to ¥502,355,777.57 in Q1 2022[4] - The net loss attributable to shareholders was ¥87,328,471.36, a 47.92% increase from a loss of ¥59,036,738.82 in the same period last year[4] - Basic and diluted earnings per share were both -¥0.195, a decrease of 46.62% from -¥0.133 in the previous year[4] - Net loss for Q1 2023 was CNY 102,510,457.16, compared to a net loss of CNY 77,955,863.57 in Q1 2022, reflecting a deterioration in performance[23] - The company reported a total comprehensive loss of CNY 102,485,693.93 for Q1 2023, compared to a loss of CNY 79,760,432.91 in the previous year[23] Cash Flow and Operating Activities - The net cash flow from operating activities improved by 59.95%, amounting to -¥149,214,873.49 compared to -¥372,615,164.88 in Q1 2022[4] - Cash flow from operating activities showed a net outflow of CNY 149,214,873.49, an improvement from a net outflow of CNY 372,615,164.88 in Q1 2022[25] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,142,691,786.97, compared to CNY 965,022,381.56 at the end of Q1 2022[26] - The company received CNY 425,310,222.02 in borrowings during Q1 2023, slightly up from CNY 424,000,000.00 in the same period last year[26] - The company’s total cash inflow from financing activities was CNY 446,193,733.87, compared to CNY 424,000,000.00 in Q1 2022[26] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥10,347,737,705.98, a 0.59% increase from ¥10,287,367,777.32 at the end of the previous year[4] - The company's total liabilities reached approximately 6.91 billion RMB, compared to 6.74 billion RMB at the beginning of the year[20] - The company's total equity decreased to approximately 3.44 billion RMB from 3.55 billion RMB at the beginning of the year[20] - The company's current assets totaled approximately 4.62 billion RMB, slightly up from 4.58 billion RMB at the beginning of the year[19] - The company's inventory increased to approximately 1.48 billion RMB from 1.35 billion RMB at the beginning of the year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,504[12] - The top shareholder, Zhejiang Ruiyang Technology Co., Ltd., holds 16.18% of the shares, with 73,228,185 shares pledged[13] Subsidiary Performance - The company achieved a total new contract amount of approximately 500 million RMB in the reporting period, with its subsidiary Hangzhou Puyu Technology Development Co., Ltd. contributing about 210 million RMB[17] - In Q1 2023, Puyu Technology reported revenue of 226 million RMB, with a net loss of 29.95 million RMB[17] Operating Costs and Expenses - Total operating costs rose to CNY 689,802,271.39, up 8% from CNY 638,851,659.23 in the previous year[22] - Research and development expenses increased to CNY 157,676,474.91, up 13.5% from CNY 138,873,659.51 in the same period last year[22] Other Income and Investment - Other income increased by 39.49% to ¥39,167,722.25, primarily due to an increase in government subsidies[10] - Investment income showed a loss of ¥6,822,704.61, worsening by 43.32% from a loss of ¥4,760,494.04 in the previous year[10] Audit Status - The first quarter report of the company is unaudited[27]

Financial Performance - The company's operating revenue for 2022 was 3.45 billion RMB, a decrease of 8% compared to the previous year[5]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -419 million RMB, a decline of 18.96% year-on-year, with losses increasing by 67 million RMB compared to the previous year[5]. - The company's operating revenue for 2022 was ¥3,450,620,276.09, a decrease of 8.00% compared to ¥3,750,514,066.26 in 2021[25]. - The net profit attributable to shareholders was -¥374,816,820.15, representing a decline of 61.25% from -¥232,438,571.77 in the previous year[25]. - The cash flow from operating activities improved significantly, with a net cash flow of -¥11,995,832.70, an increase of 96.72% compared to -¥366,149,530.54 in 2021[25]. - The basic and diluted earnings per share were both -¥0.8400, down 61.54% from -¥0.5200 in 2021[25]. - The net assets attributable to shareholders decreased by 8.15% to ¥3,228,756,373.83 from ¥3,515,301,302.78 in 2021[25]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three years[25]. Contracts and Revenue Sources - The total amount of new contracts signed by the company was approximately 4.6 billion RMB, an increase of about 12.2% year-on-year, with the subsidiary Puyutech contributing approximately 2.12 billion RMB, a growth of 58.2%[5]. - The main business revenue was CNY 3.32 billion, accounting for 96.35% of total revenue, with a year-on-year decrease of 8.28%[83]. - The revenue from instruments and related software was CNY 2.35 billion, representing 68.18% of total revenue, with a year-on-year increase of 12.76%[83]. - Domestic revenue was CNY 3.35 billion, down 9.39% year-on-year, while international revenue increased by 92.31% to CNY 99 million[81]. Research and Development - The company plans to increase R&D investment and market promotion for new products, leading to an increase in financial expenses due to rising interest-bearing debt[5]. - The company has invested a total of 3 billion RMB in R&D, maintaining a high proportion of investment to accelerate technology platform accumulation[79]. - The total R&D investment for 2022 was approximately ¥566.33 million, representing 16.41% of the operating revenue, an increase from 13.95% in 2021[93]. - The number of R&D personnel increased by 16.07% to 1,726 in 2022, accounting for 24.54% of the total workforce[93]. - The company is advancing multiple R&D projects, including a clinical protein analysis system and a digital fluorescence immunoassay system, both of which are in the market promotion phase[92]. Product Development and Innovation - The company is focused on the development of high-end analytical instruments, which are crucial for scientific research and technological innovation[36]. - The company has developed a series of new monitoring devices for environmental applications, including photochemical and greenhouse gas monitoring systems[40]. - The company has launched a new online monitoring system for emerging water pollutants, utilizing triple quadrupole mass spectrometry technology[43]. - The company has established a comprehensive carbon monitoring solution, integrating monitoring, data analysis, and simulation processes[44]. - The company has launched multiple innovative products in the high-end scientific instrument sector, achieving substantial sales growth and maintaining a leading position in technology and market[63]. Financial Management and Governance - The company does not plan to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, adhering to legal standards[126]. - The company maintains independence from its controlling shareholders in business, assets, personnel, and finance[128]. - The company has implemented a comprehensive salary and performance assessment system for its management team[139]. - The company emphasizes legal operation and integrity in tax payment, focusing on creating economic value while fulfilling social responsibilities[165]. Risks and Challenges - The company faces various risks including technology, market, accounts receivable, expansion, mergers and acquisitions, human resources, and PPP project risks[6]. - The company is addressing accounts receivable risks, as a significant portion of its total assets is tied up in receivables from government and large industrial clients[114]. - The company is enhancing its internal audit and control systems to mitigate management and operational risks associated with rapid expansion[116]. - The company is cautiously pursuing new mergers and acquisitions, having established a specialized acquisition team and an initial integration management system[117]. Market Position and Strategy - The global analytical instrument market is experiencing stable growth, with China’s market share increasing rapidly despite being relatively small[109]. - The company aims to enhance its competitiveness in the analytical instrument sector by integrating production, learning, research, and application, focusing on core technology platforms[111]. - The company plans to develop a series of innovative products tailored to high-end, diverse, and customized analytical detection needs[112]. - The company is committed to accelerating the domestic research and development and localization process of high-end analytical instruments[111]. Corporate Social Responsibility - The company respects and protects the rights of stakeholders, promoting mutual benefits with suppliers and customers[127]. - The company adheres to labor laws to protect employee rights and interests, fostering a harmonious labor relationship[166]. - The company has committed to not engaging in any competitive business or product development that may conflict with its own operations[170].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 聚光科技（杭州）股份有限公司（以下简称"公司"）定于2023年5月5日（周 五）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采 用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会或者直接进入聚光科技（杭州） 股份有限公司路演厅（https://ir.p5w.net/c/300203.shtml）参与本次年度业 绩说明会。 聚光科技（杭州）股份有限公司 关于举行2022年度网上业绩说明会的公告 出席本次说明会的人员有：公司董事长顾海涛先生、总经理韩双来先生、财 务负责人虞辉先生、董事会秘书田昆仑先生、独立董事刘菁女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 5 日（星期五）15：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面。公司将在 ...

编号：2015-002 证券代码：300203 证券简称：聚光科技 聚光科技（杭州）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □一对一沟通 | | | ■ | 其他（深交所联合深圳证监局在公司举办"践行中国梦·走 | | | 近上市公司" 投资者开放日） | | | 参与单位名称及 | 1 | 、通过上海证券、中信证券、财通证券、广发证券、西南证券、 | | 人员姓名 | | 东方证券、东北证券、中银国际、财达证券、中信建投、国信证 | | | 券、国元证券等报名的近 | 60 名中小投资者； | | | | 2、深交所信息公司、证券时报、第一财经电视、第一财经新闻 | ...

证券代码：300203 证券简称：聚光科技 编号：2016-001 聚光科技（杭州）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □一对一沟通 | | | ■ | 其他（深圳证券交易所联合高盛 -2016 深圳上市公司企业 | | | 日） | | | 参与单位名称及 | | 安联投资、汇丰环球投资管理（香港）有限公司、纽宾凯集团 | | 人员姓名 | | 有限公司、华夏基金（香港）有限公司、法国巴黎投资管理亚 | | | 洲有限公司、 | indus capital advisors(HK) ltd. 、 OLD PEAK | | | LIMITED | 、景顺投资管理有限公司、 V ...